FibroBiologics wins European patent for enhancing fibroblast therapeutic activity
Bitget2026/09/29 12:32- FibroBiologics won a European patent for methods that condition fibroblasts with platelet-rich plasma, targeting stronger regenerative activity.
- Claims cover use of cytokines including FGF-alpha or FGF-beta, with additional protection for angiogenesis-related applications.
- Patent also targets spinal disc regeneration, reinforcing the company’s disc degeneration clinical program.
- Grant expands a portfolio of more than 270 issued or pending patents across fibroblast-based therapies.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Barrick’s Marquee gold project faces hazy study timing
Japanese and South Korean stock markets open
Marvell Technology (MRVL.US) $115 billion "merger of the century" faces lukewarm reception! Stock has dropped over 40%, experts estimate only a 50% chance of completion
Marvell plans to acquire Lamington for 115 billions USD to strengthen its position in AI, but the probability of completion is only 50%. The two stocks have dropped by nearly 40% and about 35% respectively, with Chinese regulatory approval being the biggest uncertainty.
Crypto prices
More
